quartetmedicine.com
Investors - Quartet Medicine
https://quartetmedicine.com/investors
The Novartis Venture Fund. NVF) invests in innovative life science companies for areas of unmet medical need that create attractive returns for entrepreneurs and investors. The NVF is stage-agnostic, engaging in investments from seed- to later-stage life sciences companies across biotechnology, medical devices and diagnostics and currently manages over USD 1 billion in committed capital and more than 45 portfolio companies. For more information please visit www.nvfund.com. The Partners Innovation Fund.
pelotontherapeutics.com
Peloton Therapeutics
http://pelotontherapeutics.com/investors
R & D. Peloton stands on a solid financial foundation, having raised more than $60M in venture capital support to date. Peloton benefits from strong backing by The Column Group, Remeditex Ventures, Tichenor Ventures, Topspin Fund, Nextech Invest, and other investors. Peloton is well positioned to advance its promising therapies to proof of relevance clinical studies. REMEDITEX VENTURES, LLC. TICHENOR VENTURES, LLC. TOPSPIN FUND, LP. Nextech Invest is a global investment manager founded in 1998 and locate...
vpd.net
Velocity Pharmaceutical Development - We Build Drugs, Not Companies.™
http://www.vpd.net/press_releases/VPD_8.19.2013.html
Stay Connected With Velocity. We Build Drugs, Not Companies. Velocity Pharmaceutical Development and Remeditex Ventures. Announce Collaboration Agreement and Initial Co-Investment. South San Francisco, California and Dallas, Texas - August 19, 2013. In conjunction with this collaboration, both VPD and Remeditex have announced an investment by Remeditex in a VPD-managed pharmaceutical development company, Tigercat Pharma, Inc. Having Remeditex as a potential funding partner greatly expands the scope of op...
pelotontherapeutics.net
Peloton Therapeutics
http://www.pelotontherapeutics.net/investors.html
THE COLUMN GROUP (TCG). REMEDITEX VENTURES, LLC. Remeditex Ventures, a Dallas-based company, invests in high quality, innovative, early-stage biomedical projects that are judged to have commercialization potential. Its goal is to partner with early-stage researchers and entrepreneurs in Texas and Colorado, helping investigators establish commercial viability thereby making these ventures attractive to traditional investors. TICHENOR VENTURES, LLC. CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS (CPRIT).
vpd.net
Velocity Pharmaceutical Development - We Build Drugs, Not Companies.™
http://www.vpd.net/press_releases/VPD_12.17.2014.html
Stay Connected With Velocity. We Build Drugs, Not Companies. VPD 12.17.2014. Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus. Statistically Significant Data from Phase 2 Study Support Safety and Efficacy. Of Once Daily Dosing of NK-1 Antagonist, VPD-737 (serlopitant). South San Francisco, December 17, 2014. VPD-737 is safe and well tolerated. Edward Schnipper, M.D., a Founder and Chief Medical Officer at Tig...Tiger...
vpd.net
Velocity Pharmaceutical Development - We Build Drugs, Not Companies.™
http://www.vpd.net/press_releases/VPD_8.19.2013_737.html
Stay Connected With Velocity. We Build Drugs, Not Companies. Velocity Pharmaceutical Development and Tigercat Pharma Inc. Announce Submission of IND Application for VPD-737. South San Francisco, California August 19, 2013. Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus. Tigercat Pharma, Inc&...
navitorpharma.com
Navitor Investors
http://www.navitorpharma.com/about/investors.html
MTORC1 Pathway and Biology. MTORC1 and Age-Related Disease Processes.